Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Julie Kim is set to replace Christophe Weber as the new chief executive officer of Takeda Pharmaceutical Co., becoming the first woman to lead the more than 240-year-old Japanese drugmaker.

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S. business unit. As part of the executive transition, Weber will retire in June ...

PETALING JAYA, Jan 23 — PUMA Malaysia and the Football Association of Malaysia (FAM) today unveiled the new Harimau Malaya (national squad) jerseys, symbolising the start of a new era for Malaysian ...

PETALING JAYA: The Football Association of Malaysia (FAM) has confirmed that the head coach of Harimau Malaya Peter Cklamovski arrived on Wednesday (Jan 22). “The new national head coach ...

Bone-chilling temperatures couldn’t keep the crowds away from Takeda’s Kendall Square campus on Tuesday to celebrate a milestone for the Japanese drugmaker’s new R&D tower. More than 250 ...

In connection with the effectiveness of the agreement, Takeda will make an upfront payment to the Company of $200.0 million. About Keros Therapeutics, Inc. Keros is a clinical-stage ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

In what seems to be an unending series of controversies for Malaysia’s oldest university, the Universiti Malaya (UM) is again in the spotlight. This time, it’s over a Chinese New Year celebration that ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. “There's an evolution of our economic model that starts with [the] IRA (Inflation ...

Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical (4502.T), opens new tab, is looking to raise $149 million by offering about 7.3 million American depositary shares at $20.34 each.